Questions
I believe they will get cashflow positive in the short-term. Pidduck's guidance have been spot on so far.
Things I worry about:
If there are no patents applicable on those cannabinoids drugs, they will need to be the most cost-efficient at producing the molecules. On that front, I wonder if they are working on something. Anyone knows where we stand compared to competition?
Also, I hope they focus on the commercialization of pharma products like Dronabinol. We got really ***** and 1 good quarter providing ingredients to other companies that in the end decided to produce them themselves. Only providing API to big pharma is risky. IDK what kind of deal they have with them. The exclusive deal with Stada will expire soon, 2025 if I remember correctly. I hope the studies they are working on will result in their own products.
Also, if R&D is not expensive, being the first formulation on the market could be quite lucrative for a while thus having talented R&D.